$MDT is here with their latest earnings release. For Q4 2025, Medtronic reported an EPS of $1.62, exceeding expectations by $0.04, and revenues of $8.93B, reflecting a 3.94% year-over-year growth. Key highlights include an 8% surge in the cardiovascular sector and a strategic move to separate its diabetes business, enhancing focus on high-margin growth areas. However, risks include tariff impacts of $200M–$350M and gross margin headwinds.